JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications

Janus kinase inhibitors [JAKi] are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors, and are increasingly being used in the treatment of immune-mediated diseases. Tofacitinib, a non-selective JAKi, is now approved for moderate-to-severe ul...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Manasi, Kim, Eun Soo, Colombel, Jean-Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395307/
https://www.ncbi.nlm.nih.gov/pubmed/32006031
http://dx.doi.org/10.1093/ecco-jcc/jjaa017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395307/
https://www.ncbi.nlm.nih.gov/pubmed/32006031
http://dx.doi.org/10.1093/ecco-jcc/jjaa017

Ejemplares similares